Declines in Compass Pathways (CMPS) shares are generally tied to the high-beta nature of pre-revenue mental health therapeutic developers, where sentiment shifts rapidly based on broader market liquidity, clinical trial trial pacing, and general risk-off sentiment across speculative growth equities.